Welcome to our dedicated page for Opgen news (Ticker: OPGN), a resource for investors and traders seeking the latest updates and insights on Opgen stock.
OpGen Inc. (OPGN), now named CapForce Inc., reports developments tied to its repositioning from a precision medicine diagnostics company toward digital investment banking and financial technology. Recent company updates cover the name change, material agreements, capital actions, shareholder voting matters and governance decisions.
The company's historical news also includes operating and financial results for its former molecular diagnostics and bioinformatics business, including Unyvero systems and ARESdb-related assets. Other recurring items include reverse stock split actions, securities purchase arrangements, subsidiary insolvency developments and transitions affecting legacy commercial diagnostics operations.
OpGen (OTC: OPGN) announced a corporate name change to CapForce Inc. effective February 27, 2026, reflecting a strategic repositioning into digital investment banking and fintech.
The company said it expects to change its ticker symbol to CFOR as part of the rebranding to emphasize a focus on capital markets and mid‑market growth.
OpGen has received a notice from Nasdaq for not filing its quarterly report on Form 10-Q for the period ending March 31, 2024. This adds to OpGen's prior issues of not filing its annual report for 2023 on time and failing to maintain a minimum bid price of $1.00 per share. The Nasdaq Hearings Panel has given OpGen until June 3, 2024, to resolve these compliance issues. While the company is taking steps to address the concerns, the notice currently has no immediate impact on the trading of its stock on Nasdaq.
OpGen announced a 1-for-10 reverse stock split effective May 20, 2024. The split aims to increase the market price per share to meet Nasdaq's $1.00 minimum bid price requirement. The company's common stock will trade under the symbol 'OPGN' with a new CUSIP number, 68373L505. The split will reduce the number of outstanding shares from approximately 12.6 million to about 1.26 million. All stockholders will be affected proportionally, and fractional shares will be rounded up. Pacific Stock Transfer Company will manage the exchange of shares.
OpGen, Inc. announced the sale of its commercial customer contracts and Unyvero systems to Camtech Pte for $218,000. Additionally, Ares Genetics GmbH sold its assets to bioMerieux S.A. OpGen plans to work with Camtech and Curetis team to transfer U.S. Unyvero customers. OpGen also offered Camtech the opportunity to acquire its remaining inventory for $176,000. OpGen's CEO sees these transactions as preparation for potential strategic transactions like a reverse merger.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.